HIGHLIGHTS
- who: Ilona Nurmi-Lu00fcthje from the Department of Orthopedics and Traumatology, North Kymi Hospital, Kuusankoski, Finland have published the research work: Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and brief review of the literature, in the Journal: (JOURNAL)
- what: Mild APR is common with administration of the first zoledronic acid infusion.
SUMMARY
According to a recent prospective study, the risk of vertebral fracture during AI therapy was significantly lower for patients receiving denosumab or zolendronic acid therapy compared with oral bisphosphonate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.